Fortis Healthcare Limited (NSE: FORTIS) is one of India’s leading healthcare providers, offering a range of medical services across its network of hospitals and clinics. The company has a strong presence in India and internationally, with a focus on high-quality healthcare services that are affordable and accessible to all. In terms of earnings, Revenue from Operations for Q3 FY23 was ₹1,559.88 crore, a 6% increase from ₹1,466.65 crore in the same period last year. The Consolidated Net Profit was ₹142.13 crore, a slight increase from ₹141.71 crore in the same quarter last year. This quarter’s earnings per share was ₹1.72.
Revenues from the Hospital business increased by 13.3% to ₹1,267 Cr from ₹1,118 Cr in Q3FY22. The company’s focus specialties, which include oncology, gastroenterology, neurosciences, renal sciences, orthopedics, and cardiac sciences, saw a 15.8% increase in revenue contribution and now account for 60.9% of all hospital revenues. When compared to Q3FY22’s ₹388.5 Cr in revenue, Diagnostic Business reported ₹331.5 Cr in Q3FY23. The pandemic-related decrease in Covid test volumes from Q3FY22 was a major factor in the decline.